CD86+ macrophages, akin to TREM2+ subsets, have also been detected in AAA models, reinforcing their potential as therapeutic targets and supporting macrophage-directed strategies in AAA treatment [144,146]. The gene discussed is CD86; the disease is triple-A syndrome.